UCSF

Katherine Yang, PharmD

Professor
Department of Clinical Pharmacy
Yang
[email protected]
Phone: +1 415 502-6511
Fax: +1 415 476-6632
533 Parnassus Avenue, Rm 585E
San Francisco, CA 94143
United States

Links

UCSF Profiles

Educational programs

UCSF centers, institutes, and research programs

What I do

I specialize in the treatment of multi-drug resistant infections. My area of research is in the pharmacodynamic optimization of antibiotics for the treatment of multi-drug resistant gram-negative bacteria such as Pseudomonas aeruginosa. I am particularly interested in the treatment of bacterial biofilms, which are particularly difficult to treat with conventional antibiotics. I am also an infectious diseases pharmacist specialist at UCSF Health. In the School of Pharmacy, I am heavily involved in the PharmD curriculum and am currently the co-director of the Foundations course.

Departmental research area

clinical research

My research expertise

in vitro pharmacokinetic/pharmacodynamic modeling of antibiotics on Pseudomonas aeruginosa biofilms

Clinical expertise

pharmacokinetic/pharmacodynamic dose optimization, infectious diseases, antimicrobial stewardship

Degrees

MPH, University of California, Berkeley, 2001
PharmD, University of California, San Francisco, 1998
BS, Microbiology and Molecular Genetics, University of California, Los Angeles, 1994

Biography

Kathy Yang, Pharm.D., MPH is a Health Sciences Clinical Professor in the Department of Clinical Pharmacy at the University of California (UCSF) School of Pharmacy and an Infectious Diseases Clinical Pharmacist in the UCSF Medical Center. Dr. Yang specializes in the treatment of multi-drug resistant infections, particularly gram negative bacteria such as Pseudomonas aeruginosa. Her area of research focuses on the pharmacodynamic optimization of antibiotics for the treatment of biofilm-mediated infections such as cystic fibrosis.

Within the School of Pharmacy, Dr. Yang is involved in multiple aspects of the curriculum related to infectious diseases. Dr. Yang is also the co-director of Foundations, the first course of the Pharm.D. curriculum.

Research keywords

Pseudomonas aeruginosa, pharmacokinetics, biofilm, antibiotic resistance, antimicrobial stewardship, cystic fibrosis, pharmacodynamics, Pneumonia, Bacterial, cystic fibrosis, Biofilms, Voriconazole, Drug Resistance, Microbial, Antifungal Agents, Pneumonia, Ventilator-Associated, Tobramycin, Long QT Syndrome, Anti-Bacterial Agents, Nitriles, Thienamycins, Triazoles, Pseudomonas aeruginosa, Culture Media

Licensure and certifications

Licentiate in Pharmacy, California, 1998
Licentiate in Pharmacy, Nevada, 1999

Publications

Trinh TD, Strnad L, Damon L, Dzundza JH, Graff LR, Griffith LM, Hilts-Horeczko A, Olin R, Shenoy S, DeVoe C, Wang L, Rodriguez-Monguio R, Gu TM, Hampton SR, Macapinlac BAC, Yang K, Doernberg SB. Reductions in vancomycin and meropenem following the implementation of a febrile neutropenia management algorithm in hospitalized adults: An interrupted time series analysis. Infect Control Hosp Epidemiol. 2021 Jan 25; 1-8.
Yang K. What Do We Know About Remdesivir Drug Interactions? Clin Transl Sci. 2020 09; 13(5):842-844.
Huang L, Haagensen JAJ, Verotta D, Cheah V, Spormann AM, Aweeka F, Yang K. Determination of Tobramycin in M9 Medium by LC-MS/MS: Signal Enhancement by Trichloroacetic Acid. J Anal Methods Chem. 2018; 2018:7965124.
Verotta D, Haagensen J, Spormann AM, Yang K. Mathematical Modeling of Biofilm Structures Using COMSTAT Data. Comput Math Methods Med. 2017; 2017:7246286.
Haagensen J, Verotta D, Huang L, Engel J, Spormann AM, Yang K. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms. J Antimicrob Chemother. 2017 Dec 01; 72(12):3357-3365.
Trang TP, Hanretty AM, Langelier C, Yang K. Use of isavuconazole in a patient with voriconazole-induced QTc prolongation. Transpl Infect Dis. 2017 Aug; 19(4).
Haagensen JA, Verotta D, Huang L, Spormann A, Yang K. New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms. Antimicrob Agents Chemother. 2015 Jul; 59(7):4074-81.
Huang L, Haagensen J, Verotta D, Lizak P, Aweeka F, Yang K. Determination of meropenem in bacterial media by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 15; 961:71-6.
Fricks-Lima J, Hendrickson CM, Allgaier M, Zhuo H, Wiener-Kronish JP, Lynch SV, Yang K. Differences in biofilm formation and antimicrobial resistance of Pseudomonas aeruginosa isolated from airways of mechanically ventilated patients and cystic fibrosis patients. Int J Antimicrob Agents. 2011 Apr; 37(4):309-15.
Sohn AH, Schwartz JM, Yang KY, Jarvis WR, Guglielmo BJ, Weintrub PS. Risk factors and risk adjustment for surgical site infections in pediatric cardiothoracic surgery patients. Am J Infect Control. 2010 Nov; 38(9):706-10.
Yang, K MacDougall C Wiener-Kronish J. An Evidenced-based Practice in Critical Care. Epidemiology and management of antibiotic resistance in the ICU. 2010.
Steinman MA, Yang KY, Byron SC, Maselli JH, Gonzales R. Variation in outpatient antibiotic prescribing in the United States. Am J Manag Care. 2009 Dec; 15(12):861-8.
Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. Multidrug-resistant Pseudomonas aeruginosa ventilator-associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann Pharmacother. 2009 Jan; 43(1):28-35.
Zhuo H, Yang K, Lynch SV, Dotson RH, Glidden DV, Singh G, Webb WR, Elicker BM, Garcia O, Brown R, Sawa Y, Misset B, Wiener-Kronish JP. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection. Crit Care Med. 2008 Sep; 36(9):2495-503.
Lynch SV Yang K Brodie EL MacDougall C Andersen G Wiener-Kronish JP. Culture-Independent Bacterial Population Analysis - Clinical Implications for Respiratory and Other Infections. Current Respiratory Medicine Reviews. 2008; 4(1):35-9.
Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother. 2007 Sep; 41(9):1427-35.
Yang K Youmans S. Expanding the Role of the Pharmacist in Public Health. California Journal of Health-Systems Pharmacy. 2006; 18(3):14-19.
Youmans S Vogt E Yang K . Utilization of Community Pharmacies: Implications for Health Care Delivery. Harvard Health Policy Review. 2006; 7(1):180-7.
Yang K Graff L Caughey A. Blueprints Notes and Cases. Pharmacology. 2003.
Yang K, Guglielmo BJ. Patient education for H pylori: who benefits? West J Med. 2002 Mar; 176(2):97.
Make a gift
We see a time when precise therapeutics—used safely and effectively—improve the health of people everywhere.
© 2002–2021 The Regents of the University of California